Effects of the hormone desacyl ghrelin on glucose metabolism and insulin sensitivity

Acyl and desacyl ghrelin: The Yin and Yang of glucose homeostasis and insulin sensitivity? -Acute metabolic effects of desacyl ghrelin in insulin resistant patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-000022-63-DK

Enrollment

Registered

2014-02-12

Start date

2013-03-15

Completion date

Unknown

Last updated

2016-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus MedDRA version: 16.1 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders

Interventions

Product Name: Desacyl ghrelin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Desacyl ghrelin CAS Number: 313951-59-6 Current Sponsor code: DAG Other descriptive name:

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Men with type 2 diabetes - Age 18-65 years - HbA1c=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -Alcohol abuse -Malignant disease -Medications (except anti diabetics, antihypertensiva, aspirin, cholesterol lowering agents) -Any other diseases except from diabetes, hypertension, hypercholesterolemia -Participation in trials with isotopes within last 6 months -BMI>35 -Incapability to abstain from tobacco smoking during the trial days -Anorexia -Previous Torsade de Pointes -Long QTc Syndrome -Sympotatic hypotension or bradycardia -MI, unstabel angina or TIA 1.5 upper limit -Hypo- og hyper thyroidism

Design outcomes

Primary

Measure	Time frame
Main Objective: The main objective of the trial is to investigate the effects of desacyl ghrelin on insulin resistance;Secondary Objective: The secondary objectives are to investigate the effects of desacyl ghrelin on lipid and amino acid metabolism;Primary end point(s): Insulin sensitivity;Timepoint(s) of evaluation of this end point: Average of glucose infusions rates from time 90 to 120 minutes	—

Measure

Time frame

Main Objective: The main objective of the trial is to investigate the effects of desacyl ghrelin on insulin resistance;Secondary Objective: The secondary objectives are to investigate the effects of desacyl ghrelin on lipid and amino acid metabolism;Primary end point(s): Insulin sensitivity;Timepoint(s) of evaluation of this end point: Average of glucose infusions rates from time 90 to 120 minutes

—

Secondary

Measure	Time frame
Secondary end point(s): Rate of appearance and disappearance of fatty acids and amino acids;Timepoint(s) of evaluation of this end point: Average values from time 210 to 240 minutes and 330 to 360 minutes	—

Countries

Denmark

Contacts

Public ContactEsben T Vestergaard

Aarhus University

4578461631

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026